Table 13 See text for description

Sex ratio (M/F)

0.57

1.1

0.25

Age, mean (SD), years

68 ± 12

72 ± 8

0.2

IGS II, mean (SD)

27 ± 10

41 ± 17

0.006

IGS II ≥37

7 (17 %)

9 (53 %)

0.005

SOFA, median (IQR)

2 (2–4)

3 (2–4.5)

0.1

Comorbidities, n (%)

 Hypertension

25 (61 %)

13 (76 %)

0.25

 Diabetes

10 (24 %)

8 (47 %)

0.08

 Congestive heart failure

14 (34 %)

6 (35 %)

0.93

 Atrial fibrillation

31 (75 %)

13 (76 %)

0.94

 Liver cirrhosis

3 (7 %)

0

0.54

Alternate-day dosing

12 (29 %)

6 (35 %)

0.22

Indication of VKA

0.3

 Atrial fibrillation

27 (65 %)

14 (82 %)

 Prosthetic valve replacement

10 (24 %)

3 (17 %)

 Thromboembolic events

4 (9 %)

0

Daily dose (mg)

0.5 ± 0.27

0.5 ± 0.22

0.71

Timing of anticoagulant therapy (months)

65 ± 57

66 ± 92

0.97

Antiplatelet therapy

7 (17 %)

3 (17 %)

1

HAS-BLED >3

2 [1.75; 3]

3 [2; 4]

0.19

Bleeding site

0.05

 Cutaneous

12 (29 %)

2 (11 %)

 Intracranial

4 (9 %)

5 (29 %)

 Alveolar

5 (12 %)

0

 Gastrointestinal

9 (22 %)

7 (41 %)

 Gynecologic

1 (2 %)

1 (5 %)

 Hematuria

7 (17 %)

0

 Intraabdominal

3 (7 %)

1 (5 %)

 Pericardial

0

1 (5 %)

Initial prothrombin ratio (%)

10

10

0.47

Initial INR

10

15

0.14

Cephalin kaolin time (s)

76 ± 30

74 ± 38

0.85

Hemoglobin (g/dl)

9.7 ± 3.3

8.9 ± 4.4

0.54

Fall in hemoglobin level (g/dl)

1

1

0.76

Platelet count (×10³e/mm³)

308 ± 131

261 ± 134

0.25

Aspartate aminotransferase (AST) (UI/L)

27 [17–38]

68 [34–244]

0.007

AST ≥34 UI/L

12 (29 %)

11 (64 %)

0.008

Alanine aminotransferase (ALT) (UI/L)

22 [12–35]

45 [16–136]

0.08

Bilirubin (µmol/l)

20 [14–39]

35 [22–63]

0.05

Blood urea (mmol/l)

13 ± 8

22 ± 14

0.1

Serum creatinine (µmol/l)

118

153

0.22